Lynch H, Johnson J, Campbell E, Keith D, Barnett J, Gooden M, Brown S & Thompson P
Estimate the value of adding abemaciclib to endocrine therapy for high-risk hormone receptor-positive and HER2-negative early breast cancer. Under the model assumptions, adding abemaciclib was unlikely to be cost-effective at the selected threshold.
Lynch H, Johnson J, Campbell E, Keith D, Barnett J, Gooden M, Brown S & Thompson P. (n.d.). Cost Effectiveness of Abemaciclib for Early Breast Cancer in Jamaica [Abstract]. https://neb-uat.textandhues.com/publications/cost-effectiveness-of-abemaciclib-for-early-breast-cancer-in-jamaica/
